Search results for "trial design"

showing 10 items of 26 documents

Advances on mechanics, design engineering and manufacturing

2018

The theme of the present editorial is dedicated to the“Advances on Mechanics, Design Engineering and Manufac-turing” that emerge in different engineering and architecturalfields.The theme has been chosen as leitmotiv of a series ofevents that have been organized by three societies operatingin Italy, Spain and France, respectively: ADM (Associ-azione nazionale Disegno e Metodi dell’ingegneria indus-triale), INGEGRAF (Asociación Española de IngenieríaGráfica and AIP-PRIMECA (Ateliers Inter-établissementsde Productique—Pôles de Resources Informatiques pour laMECAnique). Since 2014, a series of JCM conferences havebeen organized. JCM is the acronym of “Joint Conference onMechanics, Design Engin…

0209 industrial biotechnologyEngineeringbusiness.industry0211 other engineering and technologies02 engineering and technologyMechatronicsIndustrial and Manufacturing EngineeringManufacturing engineeringProduct Design and Development Computer-Aided Design and Interactive Design020901 industrial engineering & automationIndustrial designModeling and SimulationSettore ING-IND/15 - Disegno E Metodi Dell'Ingegneria IndustrialeEngineering design processbusiness021106 design practice & managementInternational Journal on Interactive Design and Manufacturing (IJIDeM)
researchProduct

The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 2

2016

International Liver Cancer Association Congress 2015, Paris, France, 4–6 September 2015 Since its creation 9 years ago, in 2007, the International Liver Cancer Association has focused on the multidisciplinary approach to liver cancer due to advances in hepatology science and care worldwide. In its 2015 annual conference, held on 4–6 September in Paris, France, the most recent progresses in the basic biology, management and treatment of liver cancer have been presented. This report, divided into two parts, introduces and critically reviews some of the most intriguing topics discussed at the meeting.

0301 basic medicineCancer Researchmedicine.medical_specialtyPathologysurvivalliver cancer03 medical and health sciences0302 clinical medicineInternal medicinestaging systemmedicineHCC; immunotherapy; liver cancer; management; prognosis; sorafenib; staging system; survival; trial design; Carcinoma Hepatocellular; Disease Management; Humans; Liver Neoplasms; Oncology; Cancer ResearchHumansHCCDisease management (health)Staging systembusiness.industryCarcinomaLiver NeoplasmsDisease ManagementHepatocellularGeneral MedicineHepatologymedicine.disease030104 developmental biologyOncologyFamily medicinetrial designsorafenib030211 gastroenterology & hepatologyimmunotherapyprognosisbusinessLiver cancermanagementFuture Oncology
researchProduct

Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data

2016

Drug development faces the double challenge of increasing costs and increasing pressure on pricing. To avoid that lack of perceived commercial perspective will leave existing medical needs unmet, pharmaceutical companies and many other stakeholders are discussing ways to improve the efficiency of drug Research and Development. Based on an international symposium organized by the Medical School of the University of Duisburg-Essen (Germany) and held in January 2016, we discuss the opportunities and challenges of three specific areas, i.e., public-private partnerships, adaptive designs and big data. Public-private partnerships come in many different forms with regard to scope, duration and typ…

0301 basic medicineLeverage (finance)Big dataMedizinReviewAppropriate useadaptive trial design03 medical and health sciencesDrug DevelopmentInformed consentinvestigator-initiated studiesbig dataPharmacology (medical)RepurposingPharmacologyInformed Consentbusiness.industryManagement sciencelcsh:RM1-950Public relationsEuphemismpublic-private partnershipPublic–private partnership030104 developmental biologylcsh:Therapeutics. PharmacologyDrug developmentPrivacyBusinesspublic–private partnershipFrontiers in Pharmacology
researchProduct

Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.

2019

The aim of this manuscript is to discuss the viewpoint of the European Organisation for Research and Treatment of Cancer (EORTC) Gastric Cancer Taskforce and Japan Clinical Oncology Group (JCOG) Gastric Cancer Study Group on the current challenges in the multidisciplinary management of stage II-III gastric and gastro-oesophageal junction (GEJ) cancer. We seek to outline how these challenges are addressed in current trials of both groups. Key elements of future trials of EORTC and JCOG in this indication are described, and a joint vision on how multidisciplinary research of gastric and GEJ cancer patients should be organised is outlined. ispartof: EUROPEAN JOURNAL OF CANCER vol:124 pages:67-…

0301 basic medicineMaleCancer ResearchEsophageal NeoplasmsADJUVANT CHEMOTHERAPY0302 clinical medicineEUROPEAN ORGANIZATIONMultidisciplinary approachGastricPerioperativeStage (cooking)AdjuvantClinical OncologyMISMATCH REPAIR DEFICIENCYdigestive oral and skin physiologyGastro oesophageal junctionOPEN-LABELPrognosisJCOGhumanitiesEORTCOncology030220 oncology & carcinogenesisCLINICAL-RESEARCHFemaleImmunotherapyEsophagogastric JunctionRANDOMIZED PHASE-IILife Sciences & Biomedicinemedicine.medical_specialtyStage ii03 medical and health sciencesStomach NeoplasmsmedicineChemotherapyHumansNeoplasm StagingScience & Technologybusiness.industryPERIOPERATIVE CHEMOTHERAPYGeneral surgeryCancerADENOCARCINOMAPLUS OXALIPLATINmedicine.diseaseSurvival Analysisdigestive system diseases030104 developmental biologyNeoplasm stagingbusinessTRIAL DESIGNEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Evidence of bias in randomized clinical trials of hepatitis C interferon therapies

2017

Introduction: Bias may occur in randomized clinical trials in favor of the new experimental treatment because of unblinded assessment of subjective endpoints or wish bias. Using results from published trials, we analyzed and compared the treatment effect of hepatitis C antiviral interferon therapies experimental or control. Methods: Meta-regression of trials enrolling naïve hepatitis C virus patients that underwent four therapies including interferon alone or plus ribavirin during past years. The outcome measure was the sustained response evaluated by transaminases and/or hepatitis C virus-RNA serum load. Data on the outcome across therapies were collected according to the assigned arm (exp…

Adultmedicine.medical_specialtyAlternative medicineAntiviral Agentslaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialBiaslawInterferonInternal medicinemedicineHumans030212 general & internal medicineSettore SECS-S/05 - Statistica SocialeRandomized Controlled Trials as TopicPharmacologyObserver Variationbusiness.industryGeneral MedicineHepatitis CMiddle Agedmedicine.diseaseHepatitis Cinterferon randomized controlled trials bias trial design favore armTreatment OutcomeResearch Design030220 oncology & carcinogenesisCase-Control StudiesPhysical therapyInterferonsbusinessmedicine.drug
researchProduct

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale…

2021

BACKGROUND: The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated, widely used tool developed to score the clinical benefit from cancer medicines reported in clinical trials. ESMO-MCBS scores assume valid research methodologies and quality trial implementation. Studies incorporating flawed design, implementation, or data analysis may generate outcomes that exaggerate true benefit and are not generalisable. Failure to either indicate or penalise studies with bias undermines the intention and diminishes the integrity of ESMO-MCBS scores. This review aimed to evaluate the adequacy of the ESMO-MCBS to address bias generated by flawed design, im…

Data Analysis:técnicas de investigación::métodos::diseño de la investigación [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Cancer Researchbiasmedia_common.quotation_subjectclinical trial reportingESMO-MCBS:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]ReviewMedical Oncologyclinical trial implementation:Other subheadings::Other subheadings::/drug therapy [Other subheadings]:neoplasias [ENFERMEDADES]:profesiones sanitarias::medicina::medicina interna::oncología médica [DISCIPLINAS Y OCUPACIONES]Neoplasmsclinical trial analysis:Investigative Techniques::Methods::Research Design [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Agency (sociology)HumansQuality (business):Health Occupations::Medicine::Internal Medicine::Medical Oncology [DISCIPLINES AND OCCUPATIONS]health care economics and organizationsmedia_commonActuarial scienceManchester Cancer Research CentreCàncer - TractamentResearchInstitutes_Networks_Beacons/mcrcClinical study designHealth technologyGénéralitésPublication biasclinical trial designAssaigs clínics - Disseny:Neoplasms [DISEASES]Clinical trialCritical appraisalOncologyResearch DesignScale (social sciences)PsychologyESMO Open
researchProduct

VirDe: A new virtual reality design approach

2008

Virtual reality (VR), even if it does not represent any more a novel technology, is one of the most powerful tool to help designers during the development of new projects. This is proved by very numerous research activities related to this field. In this research, we have studied a new way to approach the development of a product. We present the ongoing development of a system, called VirDe, acronym of virtual design, which can allow the designers to perform the whole design process, from the modelling phase to the finite element method (FEM) simulation analysis, in a virtual reality environment. This new method allows remarkable time and money saving in the overall product design process, …

EngineeringEngineering drawingProduct designbusiness.industryVirtual realitycomputer.software_genreVirtual reality - Simulation - 3D input device - CAD modelling - FEM analysesIndustrial and Manufacturing EngineeringVirtual machineIndustrial designModeling and SimulationNew product developmentDesign processbusinessSoftware engineeringEngineering design processSettore ING-IND/15 - Disegno E Metodi Dell'Ingegneria IndustrialecomputerInstructional simulation
researchProduct

L'insegnamento della composizione architettonica nella formazione dell'industrial designer : note su una esperienza didattica a Palermo

2021

Questo contributo porta a conoscenza alcuni risultati didattici ottenuti all’interno del laboratorio di Architectural Design (10 cfu), guidato dall'autore durante l’anno accademico 19-20 presso il Dipartimento di Architettura dell’Università degli Studi di Palermo, corso di laurea in Disegno Industriale. L’obiettivo che si pone è mostrare una sintetica selezione dei progetti eseguiti dagli allievi del laboratorio e, più in generale, per riflettere sulla “tenuta” dell’insegnamento del progetto d’architettura nella formazione dell’industrial designer: una figura professionale che sempre più spesso sottrae, a quella dell’architetto, il controllo sugli interventi a “piccola scala” (allestimenti…

Industrial Designer Composizione Architettonica DesignerSettore ICAR/14 - Composizione Architettonica E Urbana
researchProduct

Chairs' welcome message

2004

In this paper we present techniques for comparison between behavioral level and register transfer level (RTL) design descriptions by mapping the designs into virtual controllers and virtual datapaths. We also discuss about how the equivalence between behavioral level and RTL designs can be defined precisely using the proposed "attribute statements" in an interactive fashion. Implementation issues as well as considerations on real life industrial design examples are presented as well.

Industrial designProgramming languageComputer sciencecomputer.software_genreHardware_REGISTER-TRANSFER-LEVELIMPLEMENTATIONcomputerEquivalence (measure theory)Register-transfer levelProceedings. Ninth IEEE International High-Level Design Validation and Test Workshop (IEEE Cat. No.04EX940)
researchProduct

Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity…

2020

Abstract Background The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is complex and multifactorial. Chronotropic incompetence (ChI) has emerged as a crucial pathophysiological mechanism. Beta‐blockers, drugs with negative chronotropic effects, are commonly used in HFpEF, although current evidence does not support its routine use in these patients. Hypothesis We postulate beta‐blockers may have deleterious effects in HFpEF and ChI. This work aims to evaluate the short‐term effect of beta‐blockers withdrawal on functional capacity assessed by the maximal oxygen uptake (peakVO2) in patients with HFpEF and ChI. Methods This is a prospective, crossover, randomized (1…

MaleChronotropicheart failure with preserved ejection fractionmedicine.medical_specialtyRandomizationchronotropic incompetenceAdrenergic beta-AntagonistsTrial Designs030204 cardiovascular system & hematologyVentricular Function Leftlaw.inventionBenzodiazepines03 medical and health sciences0302 clinical medicineQuality of lifeRandomized controlled triallawInternal medicinemedicineHumansMulticenter Studies as TopicProspective Studies030212 general & internal medicineRandomized Controlled Trials as TopicHeart FailureDose-Response Relationship Drugbusiness.industryVO2 maxStroke VolumeGeneral Medicineexercise capacityquality of lifeResearch DesignSample size determinationCardiologyFemaleDeprescribingCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusiness
researchProduct